Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated, inter ...

Intravesical bacillus Calmette-Guérin (BCG) remains the cornerstone of treatment for high-risk non–muscle-invasive bladder cancer (NMIBC). Despite decades ...

ImmunityBio IBRX enters 2026 with a commercial story that is unusually concentrated. Anktiva is the company’s first marketed ...

A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...

The principal investigator of the study leading to approval said this new immunotherapy could be a "game changer" in bladder cancer. FDA last night approved nogapendekin alfa inbakicept-pmln (NAI) ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023. This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD. Daneshmand ...

Non-muscle-invasive bladder cancer (NMIBC) has a high risk of recurrence and progression among patients without adequate Bacillus Calmette-Guérin.

Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...

Bacillus Calmette-Guérin (BCG) vaccine is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. Now, using zebrafish “avatars,” a ...

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...

Please provide your email address to receive an email when new articles are posted on . Patients with high-risk non-muscle-invasive bladder cancer who received durvalumab plus BCG had improved DFS.